Diagnostics · 9 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This retrospective observational study of 225 patients with stage IV colorectal adenocarcinoma at a Romanian tertiary hospital compared outcomes by KRAS mutation status. The KRAS wild-type group had a numerically longer median overall survival (31 months) than the KRAS-mutant group (26 months), but the difference did not reach statistical significance.
This was a single-center retrospective observational study of 225 adults with stage IV colorectal adenocarcinoma at a tertiary hospital in Bucharest, Romania. Patients were divided into KRAS-mutant (n=88) and KRAS wild-type (n=137) groups based on next-generation sequencing. The KRAS wild-type group had a median OS of 31 months compared with 26 months in the KRAS-mutant group, but this difference was not statistically significant. A significantly higher proportion of KRAS wild-type patients had diabetes (18%) compared with KRAS-mutant patients (8%). Limitations include the retrospective design, limited sample size, the 7-year study period during which treatment options changed, and the absence of mismatch repair deficiency, microsatellite instability, NRAS, and BRAF testing.
